Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
This facility marks a significant milestone in transforming the global food industr
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
e brings over 27+ years of rich pharmaceutical experience
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company
Subscribe To Our Newsletter & Stay Updated
